CNPY3

Across TCGA pan-cancer cohorts, CNPY3 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CNPY3 data layer compared with 21 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CNPY3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CNPY3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

CCRCC, COAD, and GBM are the cancer types where CNPY3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.637	1.000	.003	18	view →
COAD	DFS	Median	IV	0.493	0.944	.031	12	view →
GBM	DFS	Median	All	0.267	0.475	.004	11	view →
LSCC	DFS	Quartile	II,III,IV	0.872	0.503	.016	8	view →
HNSC	OS	Tertile	All	0.771	0.899	.011	4	view →
PDAC	DFS	Median	All	0.883	0.717	.033	4	view →
LUAD	OS	Median	All	0.757	0.969	.010	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CNPY3–CCRCC (OS)

Open the CCRCC breakdown →